Nagoya University released an interim report Friday denying its manipulation of data on clinical trials for the Diovan hypertension drug of Novartis AG.
The university was the first to deny the manipulation among five universities that conducted clinical trials of the Swiss company's drug. It became the fourth to announce a report on the clinical trials, whose data were possibly changed.Nagoya University conducted the clinical trials in question from October 2004 to July 2010 on 1,150 hypertension patients with complications such as diabetes at 46 hospitals in order to compare the effectiveness of Diovan with that of a similar drug.
Based on the trials, the university said in an article in a U.S. science journal in 2012 that fewer Diovan users were hospitalized for cardiac arrest.
Of the other universities, Kyoto Prefectural University of Medicine and Jikei University have admitted data manipulation, and Shiga University of Medical Science has said it could not rule out the possibility of manipulation.
Source: NewsOnJapan
Based on the trials, the university said in an article in a U.S. science journal in 2012 that fewer Diovan users were hospitalized for cardiac arrest.
Of the other universities, Kyoto Prefectural University of Medicine and Jikei University have admitted data manipulation, and Shiga University of Medical Science has said it could not rule out the possibility of manipulation.
Source: NewsOnJapan
